European Commission Grants Marketing Authorization For Pfizer And BioNTech's 2026-27 COVID-19 Vaccine Formula
The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force
Pfizer and BioNTech got permission to sell a new COVID vaccine designed for a newer virus variant starting in 2026-27. This shows the companies can keep updating their vaccines as the virus changes, which is one way to stay competitive in the vaccine market.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.